More recently, a correlation between KRAS mutations, increased PD-L1 expression, and increased CD8+ tumor-infiltrating lymphocytes was observed, linking KRAS mutations as a promoter of an anti-inflammatory, immunosuppressive TME, adaptive immune resistance, and tumor immunogenicity (Figure 4) [1,36]. This evidence concerns the gene CD8A and neoplasm.